Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Expression of Activin During and After Chemotherapy in Peripheral Blood of Patients with Primary Breast Cancer.

Jueckstock J, Burkhardt N, Kuhn C, Blankenstein T, Mahner S, Schindlbeck C, Janni W, Rack B, Mylonas I.

Anticancer Res. 2016 May;36(5):2153-9.

PMID:
27127117
2.

Placental Expression Patterns of Galectin-1, Galectin-2, Galectin-3 and Galectin-13 in Cases of Intrauterine Growth Restriction (IUGR).

Hutter S, Knabl J, Andergassen U, Hofmann S, Kuhn C, Mahner S, Arck P, Jeschke U.

Int J Mol Sci. 2016 Apr 7;17(4). pii: E523. doi: 10.3390/ijms17040523.

3.

Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium.

Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, Mahner S, VAN Nieuwenhuysen E, Trillsch F, Cacsire-Tong D, Chekerov R, Sehouli J, Braicu EI.

Anticancer Res. 2016 Mar;36(3):1015-22.

PMID:
26976992
4.

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.

Claussen C, Rausch AV, Lezius S, Amirkhosravi A, Davila M, Francis JL, Hisada YM, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F.

Thromb Res. 2016 Mar 2;141:39-48. doi: 10.1016/j.thromres.2016.03.002. [Epub ahead of print]

PMID:
26967531
5.

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer.

Harter P, du Bois A, Mahner S, Pfisterer J, Ortmann O, Marth C, Fink D, Hilpert F, Wagner U, Sehouli J.

Geburtshilfe Frauenheilkd. 2016 Feb;76(2):147-149.

6.

Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study.

Voigt V, Neufeld F, Kaste J, Bühner M, Sckopke P, Wuerstlein R, Hellerhoff K, Sztrókay-Gaul A, Braun M, von Koch FE, Silva-Zürcher E, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Mahner S, Harbeck N, Hermelink K.

Psychooncology. 2016 Feb 22. doi: 10.1002/pon.4102. [Epub ahead of print]

PMID:
26898732
7.

The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node.

Woelber L, Eulenburg C, Grimm D, Trillsch F, Bohlmann I, Burandt E, Dieckmann J, Klutmann S, Schmalfeldt B, Mahner S, Prieske K.

Ann Surg Oncol. 2016 Feb 8. [Epub ahead of print]

PMID:
26856721
8.

Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review).

Andergassen U, Kölbl AC, Mahner S, Jeschke U.

Oncol Rep. 2016 Apr;35(4):1905-15. doi: 10.3892/or.2016.4608. Epub 2016 Feb 2.

PMID:
26848098
9.

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer.

Trillsch F, Kuerti S, Eulenburg C, Burandt E, Woelber L, Prieske K, Eylmann K, Oliveira-Ferrer L, Milde-Langosch K, Mahner S.

Br J Cancer. 2016 Jan 19;114(2):207-12. doi: 10.1038/bjc.2015.436.

PMID:
26757261
10.

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F.

Gynecol Oncol. 2016 Mar;140(3):450-6. doi: 10.1016/j.ygyno.2015.12.025. Epub 2015 Dec 28.

PMID:
26731724
11.

Partial PTEN deletion is linked to poor prognosis in breast cancer.

Lebok P, Kopperschmidt V, Kluth M, Hube-Magg C, Özden C, B T, Hussein K, Mittenzwei A, Lebeau A, Witzel I, Wölber L, Mahner S, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von d Assen A, Müller V, Burandt E.

BMC Cancer. 2015 Dec 16;15:963. doi: 10.1186/s12885-015-1770-3.

12.

Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function.

VON Bülow C, Oliveira-Ferrer L, Löning T, Trillsch F, Mahner S, Milde-Langosch K.

Mol Clin Oncol. 2015 Sep;3(5):1067-1072. Epub 2015 Jul 1.

13.

Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.

Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A.

Int J Gynecol Cancer. 2015 Nov 19. [Epub ahead of print]

PMID:
26588236
14.

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.

Mahner S, Woelber L, Mueller V, Witzel I, Prieske K, Grimm D, Keller-V Amsberg G, Trillsch F.

Front Oncol. 2015 Oct 5;5:211. doi: 10.3389/fonc.2015.00211. eCollection 2015. Review.

15.

Fetal gender specific expression of tandem-repeat galectins in placental tissue from normally progressed human pregnancies and intrauterine growth restriction (IUGR).

Hutter S, Knabl J, Andergassen U, Mayr D, Hofmann S, Kuhn C, Mahner S, Arck P, Jeschke U.

Placenta. 2015 Dec;36(12):1352-61. doi: 10.1016/j.placenta.2015.09.015. Epub 2015 Oct 3.

PMID:
26462906
16.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI.

Tumour Biol. 2016 Mar;37(3):3009-16. doi: 10.1007/s13277-015-4031-9. Epub 2015 Sep 29.

PMID:
26419591
17.

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.

Meng X, Joosse SA, Müller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H.

Br J Cancer. 2015 Nov 3;113(9):1358-66. doi: 10.1038/bjc.2015.340. Epub 2015 Sep 22.

PMID:
26393886
18.

Sexual Activity and Function in Patients With Gynecological Malignancies After Completed Treatment.

Grimm D, Hasenburg A, Eulenburg C, Steinsiek L, Mayer S, Eltrop S, Prieske K, Trillsch F, Mahner S, Woelber L.

Int J Gynecol Cancer. 2015 Jul;25(6):1134-41. doi: 10.1097/IGC.0000000000000468.

PMID:
26098093
19.

Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions.

Grimm D, Eulenburg C, Brummer O, Schliedermann AK, Trillsch F, Prieske K, Gieseking F, Selka E, Mahner S, Woelber L.

Support Care Cancer. 2016 Jan;24(1):419-28. doi: 10.1007/s00520-015-2812-8. Epub 2015 Jun 23.

PMID:
26094599
20.

Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer.

Oliveira-Ferrer L, Heßling A, Trillsch F, Mahner S, Milde-Langosch K.

Tumour Biol. 2015 Nov;36(11):9023-30. doi: 10.1007/s13277-015-3652-3. Epub 2015 Jun 18.

PMID:
26084610
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk